Organogenesis (NASDAQ:ORGO) Sets New 12-Month High – Should You Buy?

Organogenesis Holdings Inc. (NASDAQ:ORGO) shares hit a new 52-week high during mid-day trading on Friday . The company traded as high as $5.53 and last traded at $4.93, with a volume of 11033487 shares traded. The stock had previously closed at $3.07.

Organogenesis Trading Up 102.7 %

The business has a fifty day moving average of $3.36 and a 200-day moving average of $3.22. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The company has a market capitalization of $782.27 million, a P/E ratio of -103.70 and a beta of 1.77.

Insider Buying and Selling

In related news, CEO Gary S. Gillheeney sold 55,615 shares of the stock in a transaction on Friday, December 13th. The stock was sold at an average price of $3.36, for a total value of $186,866.40. Following the transaction, the chief executive officer now directly owns 3,044,779 shares in the company, valued at $10,230,457.44. This trade represents a 1.79 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 278,116 shares of company stock worth $991,190 in the last ninety days. Corporate insiders own 36.90% of the company’s stock.

Hedge Funds Weigh In On Organogenesis

A number of large investors have recently modified their holdings of the company. Millennium Management LLC lifted its holdings in shares of Organogenesis by 2.8% in the 4th quarter. Millennium Management LLC now owns 208,420 shares of the company’s stock worth $667,000 after purchasing an additional 5,765 shares in the last quarter. ProShare Advisors LLC lifted its stake in Organogenesis by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 20,329 shares of the company’s stock valued at $65,000 after acquiring an additional 6,689 shares in the last quarter. Rhumbline Advisers lifted its stake in Organogenesis by 7.1% during the 4th quarter. Rhumbline Advisers now owns 115,266 shares of the company’s stock valued at $369,000 after acquiring an additional 7,621 shares in the last quarter. Pallas Capital Advisors LLC lifted its stake in Organogenesis by 70.8% during the 3rd quarter. Pallas Capital Advisors LLC now owns 21,823 shares of the company’s stock valued at $63,000 after acquiring an additional 9,048 shares in the last quarter. Finally, State Street Corp lifted its stake in Organogenesis by 0.6% during the 3rd quarter. State Street Corp now owns 1,459,767 shares of the company’s stock valued at $4,175,000 after acquiring an additional 9,090 shares in the last quarter. 49.57% of the stock is currently owned by institutional investors.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.